Pipeline Overview

TRACON assets include two monoclonal antibodies and have been selected to possess advantageous safety profiles that will combine easily with existing therapies.

TRC093
TRC093 Phase 1 Data Presentation at the 2008 EORTC-NCI-AACR Meeting
A recombinant humanized IgG1 monoclonal antibody that inhibits angiogenesis, tumor cell growth and metastasis by binding cleaved collagen, which is predominantly produced in the extracellular matrix of tumors. A previously filed IND for TRC093 was transferred to the Company in May 2007. We began dosing TRC093 in a Phase 1 trial of cancer patients in July 2007.

TRC105
TRC105 Phase 1 Data Presentation at the 2008 EORTC-NCI-AACR Meeting
A human chimeric monoclonal antibody that binds the essential angiogenesis target CD105 (or endoglin) that we believe may complement treatment with Avastin®, an anti-cancer antibody made by Genentech. This antibody is expected to address multiple solid tumor types, including breast, kidney and/or lung cancer and will also be developed for age-related macular degeneration (“AMD”). We began dosing TRC105 in a Phase 1 trial of cancer patients in January 2008.We expect to file an IND in AMD and begin a Phase 1 trial in AMD patients in 2009.

TRC102
TRC102 Preclinical Data Presentation at the 2007 EORTC-NCI-AACR Meeting
A small molecule inhibitor of base excision repair intended to reverse resistance to chemotherapy, including the agents used in the treatment of melanoma and lung cancer. The IND for TRC102 in combination with Temodar®, a chemotherapy drug manufactured and distributed by Schering-Plough, was approved by the United States Food and Drug Administration, or FDA, in 2006. Our research partner, Case Western University, began dosing TRC102 in combination with Temodar in a Phase 1 trial of cancer patients in February 2008.  An additional Phase I study of TRC102 combined with Alimta®, a chemotherapy drug manufactured by Eli Lilly, was initiated in cancer patients in June 2008.

TRC101
A nanoliposome technology that incorporates the apoptosis-inducing compound ceramide.